Under the accord Pall will combine its Allergro single-use biocontainer platform with its New Jersey-based partner’s CelliGen bioprocess controller system.
The companies, which claim the technology better serves “upstream applications ranging from the process development laboratory to the full-scale cGMP production suite,” will also co-market it to industry customers.
Pall president Ken Frank said the partnership extends “our Allegro single-use technology to cover the entire range of upstream bioprocessing applications.”
Frank went on to say that: “We believe these new bioreactor systems will provide our customers with greater benefits in operational simplicity, product quality assurance, and process economics.”
Bioprocessing a pal to Pall
Bioprocessing is becoming an increasingly important part of Pall’s business in recent times, reducing the impact of a drop in demand for its energy, water aerospace technologies in Q1 of its fiscal year 2010..
Pall’s biomanufacturing business also performed strongly in the following quarter, with operating profit for the division climbing 27 per cent to $62m for the three months ended January 31 on 10 per cent revenue growth.
This has seen the US processing firm undertake a number of expansions of this part of its business in the last six months, with the deal with New Brunswick being just the latest example.
In February for example, Pall launched its PallSep vibrating membrane filtration (VMF) which uses encapsulated hydrophilic 0.2 µm polyethersulfone membrane filter modules to gently separate target proteins from process fluids.
And, prior to that, the firm bought MicroReactor Technologies (MRT) to access itsminiature high-throughput process development (HTPD) systems.